News stories about Signal Genetics (NASDAQ:MGEN) have been trending somewhat positive on Tuesday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Signal Genetics earned a news impact score of 0.16 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 45.2271156458623 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

MGEN has been the topic of several recent research reports. Cowen and Company initiated coverage on Signal Genetics in a research report on Thursday, June 1st. They set an “outperform” rating on the stock. Zacks Investment Research raised Signal Genetics from a “sell” rating to a “hold” rating in a research report on Saturday, June 3rd. ValuEngine raised Signal Genetics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. Chardan Capital reaffirmed a “buy” rating and set a $26.00 target price on shares of Signal Genetics in a research report on Tuesday, July 25th. Finally, Wedbush reaffirmed a “buy” rating on shares of Signal Genetics in a research report on Friday, August 18th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $19.00.

Shares of Signal Genetics (NASDAQ:MGEN) opened at 8.74 on Tuesday. The firm’s 50-day moving average price is $10.16 and its 200 day moving average price is $11.64. Signal Genetics has a 12 month low of $0.12 and a 12 month high of $18.00. The company’s market cap is $187.76 million.

Signal Genetics (NASDAQ:MGEN) last posted its quarterly earnings data on Friday, August 11th. The medical research company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.13. Signal Genetics had a negative return on equity of 92.62% and a negative net margin of 770.31%. The business had revenue of $0.72 million for the quarter, compared to analyst estimates of $0.46 million. Equities research analysts anticipate that Signal Genetics will post ($1.52) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at

About Signal Genetics

Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.

Insider Buying and Selling by Quarter for Signal Genetics (NASDAQ:MGEN)

Receive News & Stock Ratings for Signal Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Signal Genetics Inc. and related stocks with our FREE daily email newsletter.